Genprex Inc (NASDAQ:GNPX) announced on Friday that it received the United States Adopted Names (USAN) Council’s approval to use the name quaratusugene ozeplasmid for its immunogene therapy called GPX-001.
The name ‘quaratusugene ozeplasmid’ is non-proprietary, and the approval from USAN will allow Genprex to use it for its GPX-001 immunogene therapy, which was previously called Oncoprex. The drug is the company’s flagship candidate for treating non-small cell lung cancer (NSCLC). USAN is the authority that handles the regulatory approval of generic drug names in a simple and informative manner.
Genprex pursued the use of the name as part of its drug nomenclature branding and corporate communications strategy. It also plans to seek approval for the formal proprietary use of the brand name. Such approvals are necessary for companies, especially if they plan to pursue marketing approval of their therapies.
“The USAN’s adoption of our non-proprietary name is another step toward advancing our lead drug candidate, GPX-001 for non-small cell lung cancer, toward commercialization,” stated Genprex CEO, Rodney Varner.
The name adoption will align with the company’s developments moving forward.
The CEO also noted that the company looks forward to the adoption of the newly approved brand name, especially as it aims to move forward with the drug’s further development. He also added that the company is also shifting significant efforts towards the branding campaign of the company’s novel non-viral nanoparticle delivery system under the Oncoprex name. The goal is to provide a strong differentiator for GPX-001 while also providing a strong branding identity for the delivery system, which may offer other development opportunities for other drugs.
Adopting the new name will also cover GPX-002, which is the company’s gene therapy candidate for diabetes. The company has also made some changes to its website to accommodate the new changes. Genprex maintains its focus on developing gene therapies that are life-changing for diabetes and cancer patients.
The treatments particularly target patients in regions with limited treatment options for the two types of illnesses. The innovative approach also offers a potentially superior approach to treating diabetes and cancer.